Steroids killed nine-year-old Lexie McConnell after only five and a half weeks. In August 1993, Lexie was diagnosed as having toxoplasmosis. The consultant put her on 80 mg per day of prednisolone. Immediately, she suffered severe side effects, huge weight gain , terrible pains, holes in her tongue and black stools. After nearly a month, at her parents' pleading, the doctors quickly lowered the dosage to 60 mg, 40 mg, 20 mg. In excruciating pain, Lexie was taken to a hospital, where it was discovered she'd contracted chickenpox. Four days later, she died. A few years later, another eye specialist declared that a simple course of antibiotics could have cleared up her infection. The above excerpt is from Ursula Kelly's site
Many more abuse-deterrent formulations are entering the market. In November 2014 the FDA approved Hysingla ER (hydrocodone bitartrate), an acetaminophen-free, extended-release (ER) opioid for severe pain requiring daily, long-term treatment and for which no alternatives exist. As with other abuse-deterrent forms, Hysingla ER abuse-deterrent properties may reduce, but not totally prevent, abuse of the drug. The tablet forms a thick gel and cannot be easily prepared for injection, and is difficult to crush, break or dissolve. The most common side effects of Hysingla ER are constipation, nausea, fatigue, and dizziness. Targiniq ER (oxycodone/naloxone), Oxycontin (oxycodone [reformulated]), Embeda (morphine/naltrexone), Zohydro ER (hydrocodone), Troxyca ER (naltrexone/oxycodone), Arymo ER (morphine sulfate extended-release tablet), and Vantrela ER (hydrocodone bitartrate) are other long-acting but abuse-deterrent pain medications.